Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
source https://finance.yahoo.com/news/bristol-myers-bmy-opdivo-falls-152903738.html?.tsrc=rss
Bristol-Myers (BMY) announces dismal results from a late-stage study on its immuno-oncology drug Opdivo for critical brain tumor.
source https://finance.yahoo.com/news/bristol-myers-bmy-opdivo-falls-152903738.html?.tsrc=rss
blaineonline.finance.blog 